Weintraub leaving FDA in July; OTCs to be overseen on acting basis by DeLap.
This article was originally published in The Rose Sheet
Executive Summary
FDA OTC DRUGS DIVISION WILL BE OVERSEEN BY ROBERT DELAP, MD/PhD, who is taking the helm of FDA's Office of Drug Evaluation V, which includes the Division of Over-the-Counter Drug Products, July 3. DeLap will assume the role of acting director following the departure of Office of Drug Evaluation V Director Michael Weintraub, MD. DeLap, currently deputy director of ODE V, will act as director until a permanent replacement is named; he was appointed to the newly created deputy post May 26. DeLap previously was director of FDA's Oncology Drug Products Division.